697299-78-8

Upstream product

• 455-88-9 5-nitro-2-fluorotoluene 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 13290-74-9 1-chloro-2-methyl-4-nitrobenzene 

Downstream Products

• 537705-05-8 6-iodo-N-(3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)quinazolin-4-amine 
• 1260402-39-8 5-(4-(4-(6-methylpyridin-3-yloxy)-3-methylphenylamino)quinazolin-6-yl)furan-2-carbaldehyde 
• 1260402-01-4 N-(4-(6-methylpyridin-3-yloxy)-3-methylphenyl)-6-(5-((4-methyl-1,4-azaphosphinan-1-yl)methyl)furan-2-yl)quinazolin-4-amine 
• 916496-94-1 (5-{4-[(6-iodoquinazolin-4-yl)amino]-2-methylphenoxy}-1-oxidopyridin-2-yl)methanol 
• 916496-92-9 [5-(2-methyl-4-nitrophenoxy)-1-oxidopyridin-2-yl]methanol 
• 916496-93-0 [5-(4-amino-2-methylphenoxy)-1-oxidopyridin-2-yl]methanol 
• 916496-91-8 N-(3-{4-[4-(6-hydroxymethyl-1-oxypyridin-3-yloxy)-3-methylphenylamino]quinazolin-6-yl}allyl)-2-methoxyacetamide 
• 537705-10-5 (6-iodoquinazolin-4-yl)-[3-methyl-4-(6-methylpyridin-3-yloxy)phenyl]amine hydrochloride 
• 383433-14-5 (3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}prop-2-ynyl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS

Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.

Design, synthesis and biological evaluation of lapatinib derivatives as HER1/HER2 inhibitors

Five Lapatinib derivatives were designed by structurally modifying the side chain as well as the aniline substituent. The ELISA assay showed that the derivatives retained or even improved the inhibitory activity of Lapatinib against HER1/HER2. In vitro cy

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

Highly functionalised sulfur-based silica scavengers for the efficient removal of palladium species from active pharmaceutical ingredients

The use of multidentate sulfur-based silica scavengers 1,2, and 3 as highly effective adsorbents for the removal of precious metals, specifically palladium residues in this paper, from highly functionalised synthetic intermediates and APIs is described. The synthesis and purification of the polar and electron-rich reaction products, containing multiple functional groups, from palladium-catalysed removals of commonly used protecting groups such as benzyl, benzyloxycarbonyl, and allyloxycarbonyl and Sonogashira, Suzuki, Heck, and Buchwald-Hartwig coupling reactions is reported. The significant levels of residual palladium species, typically associated with these reaction products, are successfully and rapidly removed to below acceptable regulatory levels, of less than 5 ppm, by simple, unoptimised treatment with the designed silica scavengers at room temperature. Performance aspects, including broad solvent compatibility, excellent stability, and high metal affinity, combined with large-scale availability, ease of handling, and minimal loss of API make these silica scavengers particularly useful to process development groups.

PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS

The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

A quinazoline derivative of the formula (I); wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES

The invention concerns quinazoline derivatives of the formula (I), wherein each of R1, R2, R3, R4, R5, R6, R7, X1, Q1, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS

The present invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.

QUINAZOLINE DERIVATIVES

A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.

QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.